Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Martha Gulati Added: 1 year ago
ESC Congress 2022 — In this short and practice-focused review, Dr Martha Gulati, Associate Director of the Barbra Streisand Women Heart Center and Director of CVD Prevention(Cedars-Sinai Medical Center, US) shares some her thoughts on the top 3 hot line trials. Trials covered in detail include: 00:27: TIME:The Treatment in Morning versus Evening 01:57: SECURE:A polypill strategy in secondary… View more
Author(s): Purvi Parwani Added: 1 year ago
ESC Congress 22 — In this short and practice-focused review, Dr Purvi Parwani(Loma Linda University Health, Loma Linda, CA, US) shares her thoughts on the top 3 trials. Trials covered in detail include: 00:18:DANCAVAS:Screening and intervention to prevent cardiovascular disease 03:28:DELIVER:Dapagliflozin in Heart Failure with Mildly Reduced and Preserved Ejection Fraction 05:50: SECURE: A… View more
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 1 year ago
What are the take-home messages from ESC 22 and what are the implications for practice? In this short wrap-up video of ESC 22, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) review the most impactful hot line and late-breaking trials of ESC Congress 2022. Trials covered in detail include: On clinical judgement after PCI 00:35:27:REVIVED-BCIS2: Study of… View more
Author(s): Valentin Fuster Added: 3 years ago
In the Cardiology Masters section of European Cardiology Review we bring you an insight into the career of a key contributor to the field of cardiology. In this edition, we feature Dr Valentin Fuster, Mount Sinai Hospital, New York, USA Growing up in a family of doctors – my dad was a psychiatrist, my grandfather was a general physician and my maternal grandfather was President of the… View more
Foreword

Article

Added: 3 years ago
Over the past few years the scope of cardiology has widened considerably, which is well reflected in the variety of topics in this 2006 issue of European Cardiovascular Disease. On one hand, new diagnostic methods, technical progress and effective drugs have contributed to an increased survival and a better quality of life of the cardiac patient. Yet, there is a flipside to this medal: more… View more
Author(s): Rocco Antonio Montone , Giulia Iannaccone , Maria Chiara Meucci , et al Added: 3 years ago
In December 2019, several cases of interstitial pneumonia of unknown origin were detected in Wuhan, China, and on 9 January 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the causative agent of coronavirus disease 2019 (COVID-19). Within a few weeks, the contagion spread through China and South Korea, and the outbreak rapidly extended worldwide due to… View more
Author(s): Clare Taylor , Richard Hobbs Added: 3 years ago
Heart failure is a complex clinical syndrome that results from a structural or functional cardiac abnormality. The prevalence of heart failure is likely to increase as the population ages and survival rates following myocardial infarction continue to improve.1 Morbidity and mortality rates are significant and relate to high healthcare costs in terms of hospital admissions and long-term care.2… View more
Author(s): Sebastian Schnaubelt , Andreas Hammer , Lorenz Koller , et al Added: 3 years ago
Cardiovascular disease is a major cause of morbidity and mortality worldwide. While traditional treatment protocols follow physical or pharmaceutical interventions, the mental approach of meditation has been used for centuries to induce beneficial changes to the patients’ cardiovascular risk profile. However, scientific refurbishment of this technique has in the past raised questions of… View more